NCT04375813View on ClinicalTrials.gov

Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

PHASE2RecruitingINTERVENTIONAL
Enrollment

166

Participants

Timeline

Start Date

January 25, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Non-muscle Invasive Bladder Cancer
Interventions
DRUG

eRapa

0.5mg eRapa (encapsulated rapamycin) oral capsules

DRUG

Placebos

placebo capsules visually identical to eRapa oral capsules

Trial Locations (2)

75390

RECRUITING

UT Southwestern Medical Center, Dallas

78229

RECRUITING

UT Health San Antonio, San Antonio

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Robert Svatek

OTHER